GLP-1 Meds & New Obesity Treatments: Thoughts?

The OMA statement frames medication-supported weight management as standard care, not an exception. The pipeline after GLP-1s is broad enough that the treatment landscape in 5 years looks significantly different. The ketamine/binge-eating intersection is one of the more interesting adjacencies.

The shift toward GLP-1s as first-line treatment is running ahead of the insurance coverage infrastructure - the compounding and direct-pay options filling the gap are doing the real access work right now while formulary decisions catch up with the clinical evidence.

Weight gain at 2.5mg in the first few weeks is usually water retention - the fat-loss effect at that dose often takes 4-6 weeks to show.